Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | REN | P00797 | 10/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CTSE | P14091 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24021103 | 1.00 | HDAC6 (0.53) | HDAC6HDAC1RENCTSSCTSK | |
| SCHEMBL29063032 | 1.00 | HDAC6 (0.53) | HDAC6HDAC1RENCTSSCTSK | |
| SCHEMBL16464697 | 0.88 | HDAC6 (0.60) | HDAC6HDAC1CTSSCTSKNLRP3 | |
| SCHEMBL16464699 | 0.88 | HDAC6 (0.60) | HDAC6HDAC1CTSSCTSKNLRP3 | |
| SCHEMBL3823696 | 0.86 | HDAC6 (0.52) | HDAC6HDAC1RENCTSSCTSK | |
| SCHEMBL26117548 | 0.83 | CTSS (0.46) | RENCTSSCTSKAAK1CTSD | |
| SCHEMBL26117542 | 0.83 | CTSS (0.46) | RENCTSSCTSKAAK1CTSD | |
| SCHEMBL25762965 | 0.83 | HDAC6 (0.57) | HDAC6HDAC1CTSKNLRP3 | |
| SCHEMBL29062825 | 0.82 | HDAC6 (0.56) | HDAC6HDAC1CTSKNLRP3 | |
| SCHEMBL24021106 | 0.82 | HDAC6 (0.56) | HDAC6HDAC1CTSKNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | HDAC6 285/4885HDAC1 370/4885REN 505/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | HDAC6 422/4885HDAC1 956/4885REN 1927/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | HDAC6 422/4885HDAC1 956/4885REN 1927/4885 |
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | HDAC6 422/4885HDAC1 956/4885REN 1927/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | HDAC6 404/4885HDAC1 892/4885REN 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.